Trial Profile
Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 27 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.